Kiniksa Pharmaceuticals Stock Revenue
| KNSA Stock | USD 22.32 0.28 1.27% |
Kiniksa Pharmaceuticals fundamentals help investors to digest information that contributes to Kiniksa Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kiniksa Stock. The fundamental analysis module provides a way to measure Kiniksa Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiniksa Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 270.3 M | 283.8 M |
Kiniksa | Revenue |
Kiniksa Pharmaceuticals Company Revenue Analysis
Kiniksa Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Kiniksa Pharmaceuticals Revenue | 270.26 M |
Most of Kiniksa Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiniksa Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Kiniksa
Projected quarterly revenue analysis of Kiniksa Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Kiniksa Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Kiniksa Pharmaceuticals' stock price.
Kiniksa Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Kiniksa Pharmaceuticals is extremely important. It helps to project a fair market value of Kiniksa Stock properly, considering its historical fundamentals such as Revenue. Since Kiniksa Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kiniksa Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kiniksa Pharmaceuticals' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Kiniksa Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Kiniksa Pharmaceuticals reported 270.26 M of revenue. This is 96.46% lower than that of the Biotechnology sector and 63.62% lower than that of the Health Care industry. The revenue for all United States stocks is 97.14% higher than that of the company.
Kiniksa Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiniksa Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics of similar companies.Kiniksa Pharmaceuticals is currently under evaluation in revenue category among its peers.
Kiniksa Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Kiniksa Pharmaceuticals from analyzing Kiniksa Pharmaceuticals' financial statements. These drivers represent accounts that assess Kiniksa Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kiniksa Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 597.8M | 1.1B | 807.1M | 1.0B | 1.2B | 686.0M | |
| Enterprise Value | 553.5M | 985.7M | 690.7M | 922.6M | 1.1B | 597.1M |
Kiniksa Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kiniksa Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kiniksa Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Kiniksa Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Kiniksa Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kiniksa Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kiniksa Pharmaceuticals' value.| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 742.3 K | Fmr Inc | 2024-09-30 | 696.8 K | Rice Hall James & Associates, Llc | 2024-09-30 | 649.6 K | Parkman Healthcare Partners Llc | 2024-06-30 | 647.1 K | Tang Capital Management Llc | 2024-09-30 | 628.6 K | Millennium Management Llc | 2024-06-30 | 621.9 K | Driehaus Capital Management Llc | 2024-06-30 | 615.8 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 531.3 K | Granahan Investment Management Inc.. | 2024-09-30 | 507.4 K | Blackrock Inc | 2024-06-30 | 4.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 4 M |
Kiniksa Fundamentals
| Return On Equity | -0.0215 | ||||
| Return On Asset | -0.0316 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 1.4 B | ||||
| Shares Outstanding | 41.57 M | ||||
| Shares Owned By Insiders | 4.10 % | ||||
| Shares Owned By Institutions | 97.96 % | ||||
| Number Of Shares Shorted | 4.11 M | ||||
| Price To Earning | (7.20) X | ||||
| Price To Book | 3.69 X | ||||
| Price To Sales | 4.20 X | ||||
| Revenue | 270.26 M | ||||
| Gross Profit | 173.21 M | ||||
| EBITDA | (22.86 M) | ||||
| Net Income | 14.08 M | ||||
| Cash And Equivalents | 138.21 M | ||||
| Cash Per Share | 1.99 X | ||||
| Total Debt | 12.26 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 4.13 X | ||||
| Book Value Per Share | 6.06 X | ||||
| Cash Flow From Operations | 13.3 M | ||||
| Short Ratio | 12.39 X | ||||
| Earnings Per Share | (0.12) X | ||||
| Price To Earnings To Growth | 0.25 X | ||||
| Target Price | 36.0 | ||||
| Number Of Employees | 297 | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 1.61 B | ||||
| Total Asset | 526.32 M | ||||
| Retained Earnings | (477.95 M) | ||||
| Working Capital | 212.63 M | ||||
| Current Asset | 54.44 M | ||||
| Current Liabilities | 10.39 M | ||||
| Net Asset | 526.32 M |
About Kiniksa Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kiniksa Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out Kiniksa Pharmaceuticals Piotroski F Score and Kiniksa Pharmaceuticals Altman Z Score analysis. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.